Pushkal Garg Sells 1,561 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,561 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $398,320.37. Following the completion of the transaction, the chief marketing officer now directly owns 13,537 shares of the company’s stock, valued at approximately $3,454,236.29. The trade was a 10.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Pushkal Garg also recently made the following trade(s):

• On Tuesday, February 18th, Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $251.67, for a total transaction of $389,585.16.
• On Monday, January 27th, Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00.
• On Thursday, December 12th, Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $251.00, for a total transaction of $439,752.00.
• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock traded down $6.45 during mid-day trading on Tuesday, reaching $250.00. The company had a trading volume of 910,244 shares, compared to its average volume of 691,530. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The company has a market cap of $32.25 billion, a P/E ratio of -95.42 and a beta of 0.35. The business has a fifty day simple moving average of $254.04 and a 200 day simple moving average of $263.44.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ALNY. Barclays boosted their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. Scotiabank dropped their target price on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a report on Friday. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $299.48.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several large investors have recently modified their holdings of ALNY. Huntington National Bank raised its stake in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Larson Financial Group LLC raised its stake in shares of Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 73 shares during the last quarter. Hollencrest Capital Management bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at $29,000. R Squared Ltd bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $33,000. Finally, OFI Invest Asset Management bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $35,000. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.